Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharma
Description
Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Anti-neprilysin drugs are majorly used for acute heart failure, cancer pain, hypertension, Alzheimer’s disease, and other diseases. Most commonly used anti-neprilysin is Sacubitril/valsartan, which is sold under the brand name, Entrest. It consists of neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan. Entrest was first manufactured by Novartis International AG in 2015. After the arrival of this drug in the market, there has been a reduction in the rate of cardiovascular deaths and hospitalization related to heart failure. Due to the increasing prevalence of heart failure, the U.S.FDA granted fast track designation to Entresto in 2015, which supports FDA’s efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet unmet medical needs of patients.
Market Dynamics
The increasing prevalence of acute heart failure is expected to highly contribute to the anti-neprilysin market growth over the forecast period. For instance, according to the data published in the Continuing Cardiology Education Journal in 2017, heart failure (HF) is a major public health problem, affecting a total of 26 million people worldwide in 2014. Furthermore, according to the American Heart Association report, the prevalence of acute heart failure in the U.S. in 2012 was 5.7 million, representing 2.2% of the population. The projection is that HF prevalence will increase by 46% by 2030, resulting in over 8 million adults with HF in the U.S. in 2030.
However, the anti-neprilysin market growth is expected to be hampered over the forecast period, owing to the side effects and adverse effects associated with anti-neprilysin drugs. For instance, the drug called Entresto (sacubitril and valsartan), a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, might exhibit serious side effects such as low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, dizziness, and kidney (renal) failure. Such side effects can create life-threating conditions if not consumed under expert supervision.
Key features of the study:
This report provides in-depth analysis of the global anti-neprilysin market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global anti-neprilysin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global anti-neprilysin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-neprilysin market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Anti-Neprilysin Market, By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
Global Anti-Neprilysin Market, By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
Global Anti-Neprilysin Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-Neprilysin Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bioprojet SCR*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc.
Cipla Limited
Oceanic Pharmachem Pvt. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
Anti-neprilysin drugs are majorly used for acute heart failure, cancer pain, hypertension, Alzheimer’s disease, and other diseases. Most commonly used anti-neprilysin is Sacubitril/valsartan, which is sold under the brand name, Entrest. It consists of neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan. Entrest was first manufactured by Novartis International AG in 2015. After the arrival of this drug in the market, there has been a reduction in the rate of cardiovascular deaths and hospitalization related to heart failure. Due to the increasing prevalence of heart failure, the U.S.FDA granted fast track designation to Entresto in 2015, which supports FDA’s efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet unmet medical needs of patients.
Market Dynamics
The increasing prevalence of acute heart failure is expected to highly contribute to the anti-neprilysin market growth over the forecast period. For instance, according to the data published in the Continuing Cardiology Education Journal in 2017, heart failure (HF) is a major public health problem, affecting a total of 26 million people worldwide in 2014. Furthermore, according to the American Heart Association report, the prevalence of acute heart failure in the U.S. in 2012 was 5.7 million, representing 2.2% of the population. The projection is that HF prevalence will increase by 46% by 2030, resulting in over 8 million adults with HF in the U.S. in 2030.
However, the anti-neprilysin market growth is expected to be hampered over the forecast period, owing to the side effects and adverse effects associated with anti-neprilysin drugs. For instance, the drug called Entresto (sacubitril and valsartan), a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, might exhibit serious side effects such as low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, dizziness, and kidney (renal) failure. Such side effects can create life-threating conditions if not consumed under expert supervision.
Key features of the study:
This report provides in-depth analysis of the global anti-neprilysin market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global anti-neprilysin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global anti-neprilysin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-neprilysin market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Anti-Neprilysin Market, By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
Global Anti-Neprilysin Market, By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
Global Anti-Neprilysin Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-Neprilysin Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Others
By Indication:
Acute Heart Failure
Cancer Pain
Hypertension
Alzheimer’s Disease
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bioprojet SCR*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc.
Cipla Limited
Oceanic Pharmachem Pvt. Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
168 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- New Product Launches/Approvals
- Mergers & Acquisitions
- Porter’s Analysis
- PEST Analysis
- 4. Global Anti-Neprilysin Market COVID-19 Impact Analysis
- Pre-COVID Market Analysis
- Post – COVID Market Analysis
- Strategies
- 5. Global Anti-Neprilysin Market, By Drug Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Sacubitril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- TD-0714
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- STR-324
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- PL-265
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- LHW-090
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Anti-Neprilysin Market, By Indication, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Acute Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Cancer Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Alzheimer’s Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 7. Global Anti-Neprilysin Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 8. Global Anti-Neprilysin Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- 9. Competitive Landscape
- Company Profiles
- Bioprojet SCR
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pharmaleads SA
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Theravance Biopharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Oceanic Pharmachem Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 32 market data tables and 34 figures on "Global Anti-Neprilysin Market” - forecast to 2028”
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
